Prevention of Recurrence of Diverticulitis

NCT00545103 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

592

Enrollment

INDUSTRY

Sponsor class

Conditions

Diverticulitis

Interventions

DRUG: SPD476, MMX™ mesalazine, 1.2g extended release tablet
DRUG: SPD476, MMX™ mesalazine, 2.4g extended release tablet
DRUG: SPD476, MMX™ mesalazine, 4.8g extended release tablet
DRUG: Placebo

Sponsor

Shire